- Home
- REGCP vs PHVS Comparison
REGCP vs PHVS Comparison
Compare REGCP & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGCP
- PHVS
- Stock Information
- Founded
- REGCP N/A
- PHVS 2015
- Country
- REGCP United States
- PHVS Switzerland
- Employees
- REGCP 497
- PHVS N/A
- Industry
- REGCP
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- REGCP
- PHVS Health Care
- Exchange
- REGCP Nasdaq
- PHVS Nasdaq
- Market Cap
- REGCP N/A
- PHVS 980.3M
- IPO Year
- REGCP N/A
- PHVS 2021
- Fundamental
- Price
- REGCP $23.72
- PHVS $17.07
- Analyst Decision
- REGCP
- PHVS Buy
- Analyst Count
- REGCP 0
- PHVS 6
- Target Price
- REGCP N/A
- PHVS $37.17
- AVG Volume (30 Days)
- REGCP N/A
- PHVS 54.0K
- Earning Date
- REGCP N/A
- PHVS 08-13-2025
- Dividend Yield
- REGCP N/A
- PHVS N/A
- EPS Growth
- REGCP N/A
- PHVS N/A
- EPS
- REGCP N/A
- PHVS N/A
- Revenue
- REGCP N/A
- PHVS N/A
- Revenue This Year
- REGCP N/A
- PHVS N/A
- Revenue Next Year
- REGCP N/A
- PHVS N/A
- P/E Ratio
- REGCP N/A
- PHVS N/A
- Revenue Growth
- REGCP N/A
- PHVS N/A
- 52 Week Low
- REGCP N/A
- PHVS $11.51
- 52 Week High
- REGCP N/A
- PHVS $25.50
- Technical
- Relative Strength Index (RSI)
- REGCP 61.68
- PHVS 50.14
- Support Level
- REGCP $23.14
- PHVS $16.78
- Resistance Level
- REGCP $23.31
- PHVS $17.53
- Average True Range (ATR)
- REGCP 0.24
- PHVS 1.09
- MACD
- REGCP 0.07
- PHVS 0.00
- Stochastic Oscillator
- REGCP 100.00
- PHVS 29.50
About REGCP Regency Centers Corporation
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 483 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.